Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension (TREAT-IIH)

November 12, 2026 updated by: Robert Mallery, Brigham and Women's Hospital

Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension: A Randomized, Double-Masked, Placebo-Controlled Phase 2 Trial of Adjunctive Tirzepatide

The goal of this clinical trial is to learn if tirzepatide, a dual GIP/GLP-1 receptor agonist, helps to treat idiopathic intracranial hypertension (IIH) when added to acetazolamide, which is the standard medical therapy for IIH. The main questions it aims to answer are:

  • Does tirzepatide lower the mean daily acetazolamide dose at 12 months?
  • Does tirzepatide add-on therapy improve the likelihood of remission of IIH, improve weight loss, reduce cumulative acetazolamide exposure, improve ophthalmic outcome measures, improve normalization of intracranial hypertension as measured by lumbar puncture (LP) opening pressure, improve headache and quality of life measures and, improve MRI findings of intracranial hypertension?

Investigators will compare tirzepatide to a placebo/sham injection in patients who are treated with a predefined dosing schedule of acetazolamide that adjusts based upon the response of papilledema and other IIH symptoms such as headache.

In addition to receiving treatment with acetazolamide, participants will:

  • Receive weekly tirzepatide injections or a placebo/sham injection for 12 months, followed by 12 months of open-label observation.
  • Attend clinic visits at enrollment and months 1, 2, 3, 5, 7, 10, and 12 for neuro-ophthalmic examination and testing.
  • During other months meet with investigator or research assistant by phone for symptom documentation and medication adjustment.
  • Keep a record of any significant of days with headache for more than three hours or when a medication was taken for acute treatment of headache.

Study Overview

Detailed Description

Background. Acetazolamide is the current standard medical therapy for IIH and acts through inhibiting CSF production by the choroid plexus epithelium. The IIH Treatment Trial showed that acetazolamide improves visual field mean deviation, papilledema, and weight loss versus placebo, but the absolute effects were modest, headache was not significantly improved, and tolerability of acetazolamide remains a limitation. Tirzepatide and other GLP-1 agonists have potential benefit in IIH since they are effective for weight loss, and IIH can be put into remission with roughly 25% weight loss. Direct lowering of ICP by a mechanism similar to acetazolamide was also demonstrated for exenatide, another GLP-1 agonist. It is unclear if this ability extends to other members of the GLP-1 agonist class, but it is an appealing possibility.

Design. This is a single-center, randomized, double-masked, placebo-controlled, parallel-group phase 2 trial, reported per CONSORT 2025. Randomization is 1:1, administered by the BWH Research Pharmacy, stratified by (a) papilledema grade/visual loss severity and (b) BMI category, using permuted blocks of varying size. Participants, treating clinicians, outcome assessors, and analysts are masked; only unblinded pharmacy staff know allocation.

Intervention. All participants receive extended-release acetazolamide starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), and up-titrated to a maximum of 4 g/day. Acetazolamide dose is titrated at study visits by predefined rules based on perimetric mean deviation, papilledema (Frisén grade, OCT pRNFL), and a 14-day headache score. Participants also self-inject weekly tirzepatide or matching placebo starting at 2.5 mg one week after acetazolamide initiation, increasing monthly (5, 7.5, 10, 12.5 mg) to a maximum of 15 mg weekly as tolerated. All participants receive standardized nutrition and exercise guidance.

Visits. Screening/baseline, then visits at months 1, 2, 3, 5, 7, 10, and 12, with telephone or video contacts at months 4, 6, 8, 9, and 11. Assessments include visual acuity, automated perimetry (HVF 24-2 SITA Standard), OCT (Cirrus; Spectralis at baseline and 12 months), OCT angiography, fundus photography, weight and abdominal circumference, headache/quality-of-life/sleep questionnaires, lumbar puncture at month 12, and DXA and MRI at baseline and 12 months. After month 12, participants are followed open-label through month 24.

Primary endpoint is mean daily acetazolamide dose at the 12-month visit in participants with baseline BMI ≥27.0.

Statistics. Sample size is based on detecting a 375 mg/day difference (SD 450 mg, two-sided alpha 0.05, 80% power), requiring about 47 completers, inflated for 30% loss to follow-up. The primary analysis is a mixed linear model adjusted for stratification factors with a random site intercept. One interim analysis is planned using a group-sequential design (Lan-DeMets O'Brien-Fleming alpha spending) with a one-time promising-zone sample size adaptation.

Safety. Adverse events are graded with CTCAE v6.0. Medical and statistical monitors review safety data. Predefined criteria govern withdrawal and treatment failure.

Study Type

Interventional

Enrollment (Estimated)

75

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Eleonore Kugener, MS
  • Phone Number: 617-525-3610
  • Email: IIH-TRI@mgb.org

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02446
        • Brigham and Women's Hospital
        • Sub-Investigator:
          • Marc Bouffard, MD
        • Contact:
        • Contact:
        • Principal Investigator:
          • Robert Mallery, MD
        • Sub-Investigator:
          • Bart Chwalisz, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • IIH with papilledema, adapted from the 2013 diagnostic criteria and the modified Dandy criteria used in the IIH Treatment Trial:

    (i) Papilledema confirmed by a neuro-ophthalmologist (ii) Lumbar puncture opening pressure >25 cm CSF within 6 weeks of enrollment with normal CSF constituents; if opening pressure is 20-25 cm CSF, at least one of: venous pulsatile tinnitus, sixth cranial nerve palsy, Frisén grade ≥2 papilledema with pseudopapilledema excluded in at least one eye, or bilateral transverse venous sinus stenosis (iii) MRI and MRV of the brain showing no cause of secondary intracranial hypertension (e.g., tumor, hydrocephalus, venous sinus thrombosis)

  • BMI ≥25

  • Able to provide informed consent

Exclusion Criteria:

  • Treatment for IIH for more than 30 days in the prior year with any agent (acetazolamide, topiramate, furosemide, zonisamide, GLP-1 or dual GLP-1/GIP agonist); if on acetazolamide in the prior month, dose must not have exceeded 1 g/day
  • IIH relapse at prescreen/screen
  • Prior intracranial shunting, venous sinus stenting, or optic nerve sheath fenestration
  • Bariatric surgery within the past year
  • New cranial nerve dysfunction other than papilledema and sixth nerve palsy
  • Major CT/MRI abnormalities suggesting secondary intracranial hypertension or alternate diagnosis (e.g., hydrocephalus, Chiari malformation, dural AV fistula, venous sinus thrombus, retrobulbar optic nerve enhancement suggesting optic neuritis)
  • History of optic neuritis, multiple sclerosis, MOG antibody disease, neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, or seropositivity for MOG or aquaporin-4 antibodies
  • Exposure for >7 days within 2 months of symptom onset to an oral drug, substance, or disorder potentially affecting ICP (e.g., vitamin A derivatives, tetracyclines, growth hormone, lithium, corticosteroids)
  • CSF leak confirmed by beta-2 transferrin within 1 month of enrollment
  • Media opacity precluding adequate OCT signal strength and Frisén grading
  • Unreliable automated perimetry (≥30% fixation losses, ≥20% false positives or negatives) at screening
  • PMD of -15 dB or worse on reliable perimetry
  • Comorbid condition requiring diuretics, systemic steroids, or other ICP-lowering agents including topiramate or zonisamide (nasal, inhaled, or topical steroids permitted)
  • Intraocular pressure currently >28 mmHg or >30 mmHg at any time in the past
  • Refractive error greater than ±8.00 sphere or ±3.00 cylinder in either eye if associated with anatomic abnormalities that could cause visual loss
  • Optic disc drusen on fundus examination or OCT
  • Other disorders causing visual loss except refractive error and amblyopia
  • Lab abnormalities or conditions contraindicating acetazolamide (severe anemia, leukopenia, thrombocytopenia, renal failure, hepatic disease, calcium phosphate or calcium oxalate nephrolithiasis)
  • Lab abnormalities or conditions contraindicating GLP-1/GIP agonist use, including type 1 diabetes, diabetic retinopathy, diabetes managed with insulin or a secretagogue, current hypoglycemia, gallbladder disease, pancreatitis, or personal or family history of medullary thyroid cancer
  • Pregnancy, or unwillingness of participants of childbearing potential to use two methods of birth control, including a non-pharmacologic barrier method, during the study and for 1 month after
  • Breastfeeding, unless willing to stop by the baseline visit

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Acetazolamide + Tirzepatide

Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous tirzepatide starting 2.5 mg and escalated monthly as tolerated to a maximum of 15 mg weekly, for 12 months; standard nutrition and exercise counseling.

Weekly subcutaneous self-injection via autoinjector, starting 1 week after acetazolamide initiation at 2.5 mg and increasing every month to 5, 7.5, 10, 12.5, and 15 mg weekly as tolerated. Down-titration by one step and discontinuation at 2.5 mg are allowed for intolerance. Other names: Mounjaro; Zepbound.

Extended-release capsules, starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), titrated at study visits in 500 mg steps by predefined rules, maximum 4 g/day.

Placebo Comparator: Acetazolamide + Placebo

Extended-release acetazolamide titrated per protocol (up to 4 g/day) plus weekly subcutaneous placebo injection on the same escalation schedule, for 12 months; standard nutrition and exercise counseling.

Extended-release capsules, starting at 500 mg twice daily (or 1,000 mg twice daily for Frisén grade 3 papilledema or PMD worse than -7 dB), titrated at study visits in 500 mg steps by predefined rules, maximum 4 g/day.

Weekly subcutaneous placebo injection matched to tirzepatide in appearance and delivery device, with the same dose-escalation schedule.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean daily acetazolamide dose at 12 months
Time Frame: 12 months

Mean daily acetazolamide dose (mg/day) at 12 months in participants with baseline BMI ≥27.0

12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative acetazolamide dose
Time Frame: Baseline to 12 months

Area under the curve (cumulative dose) of acetazolamide over the study

Baseline to 12 months
Between-group comparison of acetazolamide dose at each study visit
Time Frame: Months 1, 2, 3, 5, 7, 10, 12
Months 1, 2, 3, 5, 7, 10, 12
Time to initiation of acetazolamide down-titration (days)
Time Frame: Baseline to 12 months
Baseline to 12 months
Remission rate (off acetazolamide)
Time Frame: Baseline to 15 months

Proportion of participants off acetazolamide (remission) at 12 months and sustained through the subsequent visit.

Baseline to 15 months
Best-corrected visual acuity
Time Frame: Baseline to 12 months

Change in best-corrected visual acuity (ETDRS, logMAR) in each eye. ≥0.3 logMAR (15-letter) change considered significant difference.

Baseline to 12 months
Visual field perimetric mean deviation
Time Frame: Baseline to 12 months

Change in perimetric mean deviation (HVF 24-2 SITA Standard)

Baseline to 12 months
Papilledema Frisén grade
Time Frame: Baseline to 12 months

Change in Frisén papilledema grade from fundus photographs (masked grader), and mean grade at each visit.

Baseline to 12 months
Peripapillary retinal nerve fiber layer (pRNFL) thickness
Time Frame: Baseline to 12 months

Change in mean pRNFL thickness (microns) measured using optical coherence tomography (Cirrus device)

Baseline to 12 months
Combined ganglion cell-inner plexiform layer (GCIPL) thickness
Time Frame: Baseline to 12 months

Change in macular ganglion cell-inner plexiform layer (GCIPL) thickness (Cirrus, microns) measured using optical coherence tomography.

Baseline to 12 months
Peripapillary capillary density on optical coherence tomography angiography (OCT-A)
Time Frame: Baseline to 12 months

Change in peripapillary capillary density on OCT-A (Cirrus)

Baseline to 12 months
Change in lumbar puncture opening pressure
Time Frame: Baseline to 12 months

LP opening pressure measured in cm cerebrospinal fluid (CSF)

Baseline to 12 months
Proportion of patients with new spontaneous cerebrospinal fluid leak
Time Frame: Baseline to 12 months
Baseline to 12 months
Composite National Eye Institute Visual Function Questionnaire 25 (VFQ-25) plus 10-item neuro-ophthalmology supplement score
Time Frame: Baseline to 12 months

Measure of vision-related quality of life and self-reported health status on a scale of 0-100. A higher score indicates better quality of life.

Baseline to 12 months
Migraine disability assessment test (MIDAS)
Time Frame: Baseline, months 3, 7, 12

5-item questionnaire measuring headache-related disability over a 3 month period. Score is the sum of days from individual questions. Higher scores signify greater headache disability. Score ranges from 0-270.

Baseline, months 3, 7, 12
Headache impact test (HIT-6)
Time Frame: Baseline, months 3, 7, 12

6 item questionnaire measuring how headaches affect daily life, work and social activities. Score ranges from 36 (no impact) to 78 (severe impact).

Baseline, months 3, 7, 12
14-day headache score
Time Frame: Baseline, months 1-12

Count of days with headache lasting more than 4 hours or requiring acute medical treatment within the prior 14 days.

Baseline, months 1-12
Time to symptom control
Time Frame: Baseline to 12 months

Time (days) to symptom control (<4 symptom days/month of headache, pulsatile tinnitus, or transient visual obscuration).

Baseline to 12 months
Proportion with symptom control
Time Frame: Baseline to 12 months

Proportion of patients with symptom control (<4 days/month of headache, pulsatile tinnitus, or transient visual obscuration)

Baseline to 12 months
Brain fog scale score
Time Frame: Baseline to months 3, 7, 12

23 item questionnaire with total score ranging from 0 to 92. Higher scores indicate increased levels of brain fog.

Baseline to months 3, 7, 12
Percent reduction in body weight
Time Frame: Baseline to 12 months

Percent reduction in body weight. Positive value represents weight loss and negative value represents weight gain.

Baseline to 12 months
Body Mass Index (BMI)
Time Frame: Baseline to 12 months

Change in BMI measured in kg/m2. Positive value represents an increase in BMI and a negative value represents a decrease in BMI.

Baseline to 12 months
Abdominal circumference
Time Frame: Baseline to 12 months

Change in abdominal circumference (cm). Positive value represents increase in circumference, and negative value represents a decrease in circumference.

Baseline to 12 months
Body fat mass
Time Frame: Baseline to 12 months

Change in dual-energy x-ray absorptiometry (DXA) measure of body fat mass (kg). Positive value represents an increase in body fat mass, and negative value represents a reduction in body fat mass.

Baseline to 12 months
Percent body fat
Time Frame: Baseline to 12 months.

Change in dual-energy x-ray absorptiometry (DXA) measures of percent body fat. Positive value represents an increase in percent body fat, and negative value represents a reduction in percent body fat.

Baseline to 12 months.
Android/gynoid ratio
Time Frame: Baseline to 12 months

Dual-energy x-ray absorptiometry (DXA) measure of android/gynoid ratio change. A/G ratio is the percentage or mass of android (abdominal) fat divided by the gynoid (hip/thigh) fat. A higher ratio (>1.0) indicates more weight is carried in the midsection. A lower ratio (<1.0) indicates more weight is carried in the hips and thighs. Increase in A/G ratio indicates an increase in abdominal/visceral fat relative to hip/thigh fat, while a decrease in A/G ratio indicates a reduction in abdominal/visceral fat relative to hip/thigh fat.

Baseline to 12 months
Bone mineral density
Time Frame: Baseline and 12 months.

Change in dual-energy x-ray absorptiometry (DXA) measure of bone mineral density (g/cm2). Positive value represents an increase in bone mineral density, and negative value represents reduction in bone mineral density.

Baseline and 12 months.
Structural magnetic resonance imaging (MRI) features of intracranial hypertension
Time Frame: Baseline to 12 months

Change in the number of structural MRI features of intracranial hypertension (partially empty sella, optic nerve sheath distention, posterior globe flattening, and presence of transverse venous sinus stenosis). Score ranges from -4 to 4. Negative score indicates resolution of findings, and a positive score indicates development of additional findings.

Baseline to 12 months
Pituitary gland height
Time Frame: Baseline to 12 months

Maximum pituitary gland height (mm) measured orthogonal to the sellar floor on mid-sagittal T1 weighted MRI sequence.

Baseline to 12 months
Optic nerve sheath diameter (mean)
Time Frame: Baseline and 12 months

Maximum diameter of the optic nerve sheath as measured on axial T2 weighted MRI within the orbit, averaged between right and left

Baseline and 12 months
Combined conduit score (CCS)
Time Frame: Baseline to 12 months

Using 3D T1-weighted MRI and MR venogram time-of-flight sequences, each transverse-sigmoid sinus conduit (right and left) is evaluated between the torcula and distal sigmoid sinus. The degree of narrowing on each side is assigned a value: 0 - aplastic or flow gap; 1 - hypoplastic or narrowed to <25% expected diameter; 2 - narrowed to 25-50% expected diameter; 3 - narrowed to 50-75% expected diameter; 4 - narrowed to 75-100% expected diameter). The CCS is the sum of the scores of the right and left side and ranges from 0 to 8. From Farb et al. 2003.

Baseline to 12 months
Diffusion tensor imaging along the perivascular space (DTI-ALPS) index
Time Frame: Baseline to 12 months.

Change in ALPS index. It is calculated as a ratio of water diffusivity values measured along different axes in specific white matter regions near the lateral ventricles to isolate perivascular diffusivity. ALPS indices are unitless. An increase in ALPS index represents an increase in extracellular/glymphatic fluid transit.

Baseline to 12 months.
Epworth Sleepiness Scale (ESS)
Time Frame: Baseline to 12 months

Change in ESS. Score ranges from 0 to 24. Increase in ESS indicates worsened symptoms related to obstructive sleep apnea.

Baseline to 12 months
STOP-Bang score (S-Snoring; T-Tired; O-Observed; P-Pressure; B-BMI; A-Age; N-Neck; G-Gender)
Time Frame: Baseline to 12 months

Change in STOP-Bang score. Score ranges from 0 to 8. Increase in STOP-Bang indicates worsened symptoms related to obstructive sleep apnea (OSA).

Baseline to 12 months
Apnea-hypopnea index (AHI)
Time Frame: Baseline to 12 months.

Change in apnea-hypopnea index (AHI) in patients with obstructive sleep apnea (OSA) who also complete a follow up sleep study at 12 months. AHI are the number of breathing disturbances/hour during sleep. An increase in AHI indicates worsening of sleep disorder breathing/OSA, while a decrease in AHI indicates improvement.

Baseline to 12 months.
Adverse Events
Time Frame: Baseline to 24 months

Number of participants with adverse events (AE) (CTCAE v6.0)

Baseline to 24 months
Serious Adverse Events
Time Frame: Baseline to 24 months

Number of participants with severe adverse events

Baseline to 24 months
Treatment-related withdrawals
Time Frame: Baseline to 12 months

Number of participants with treatment-related withdrawals

Baseline to 12 months
Treatment failures
Time Frame: Baseline to 12 months

Number of patients with treatment failures

Baseline to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Robert Mallery, MD, Massachusetts General Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

May 1, 2030

Study Completion (Estimated)

May 1, 2030

Study Registration Dates

First Submitted

October 28, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe